Axa Advisors Oct 2015 - Jun 2017
Financial Professional
Northwestern Mutual Oct 2015 - Jun 2017
Director of Financial Planning
Shamrock Asset Management Jul 2012 - Sep 2015
Managing Director
Chase Dec 2011 - Jun 2012
Vice President Investments - Financial Advisor
Wells Fargo Jan 2011 - Aug 2011
Regional Bank Private Banker
Education:
New Mexico State University 1994 - 1998
Bachelors, Bachelor of Arts, Marketing
Slippery Rock University of Pennsylvania 1992 - 1994
Skills:
Investments Financial Planning Wealth Management Business Development Retirement Planning Financial Services Tax Advantaged Investment Strategies
Since these therapies are unbelievably effective for leukemia, Novartis pricing power is high, said Thomas Shrader, biotechnology analyst at Stifel. That means Kite could piggyback off Novartis price, even though its therapy is aimed at non-Hodgkins lymphoma, which has a lower response rate to
Date: Aug 30, 2017
Category: Health
Source: Google
US FDA clears ovarian cancer drug for hard-to-treat disease
"This approval gives Clovis the chance to build a market in this space before the approval of Tesaro's niraparib," stated Stifel analyst Thomas Shrader, in a note to investors. He has a "Buy" rating on Clovis.
Date: Dec 20, 2016
Category: Health
Source: Google
What Will Pfizer Inc Gain From Medivation Inc Win?
potential worth an offer of $70 per share, while Barclays projected an offer in the range $62.7-72.5. Stifel analyst Thomas Shrader had forecasted the cancer drug maker to win a takeover price of as high as $85 apiece. Pfizers takeover bid thus presents a price much higher than what the Street expected.
13 after the drugmaker said an experimental multiple sclerosis drug, opicinumab, failed in a midstage clinical trial. Stifel Nicolaus analyst Thomas Shrader said opicinumab is a key product for Biogen. He wrote that Biogen's MS drug Tecfidera has stalled and that newer therapies could hurt sales o
Date: Jun 07, 2016
Category: Business
Source: Google
Can genetically modified mosquitoes snuff out the Zika virus?
area of about 5,000 people to one where as many as 60,000 reside. "Whether this situation in Brazil represents a real commercial opportunity or just a change to validate the Oxitec technology on a grand scale is unclear," Thomas Shrader, an analyst at Stifel Nicolaus wrote in a recent research note.
Date: Jan 29, 2016
Category: Health
Source: Google
Flickr
Googleplus
Thomas Shrader
Work:
Medical Imaging Resources, Inc. - Marketing (2009)
Education:
Eastern Michigan University - International Business
Thomas Shrader
Youtube
2020 OL Thomas Shrader (2018) Season Highlights
2020 OL Thomas Shrader (Venice, FL / Venice HS) .
Duration:
4m 50s
Florida State Recruiting - Warchant.com Proje...
Michael Langston of Warchant.com shares his scouting report along with...
Duration:
4m 6s
2020 OL Thomas Shrader (U DAY Feb 2019) Highl...
2020 OL Thomas Shrader (Venice, FL / Venice HS) .
Duration:
1m 47s
Thomas Shrader Interview: November 17
Courtesy : Thomas Shrader meets with the media following Tuesday's pr...